The INSPIRE-Lung Study

Last updated: November 7, 2025
Sponsor: Hackensack Meridian Health
Overall Status: Completed

Phase

N/A

Condition

Non-small Cell Lung Cancer

Lung Cancer

Cancer

Treatment

LungTalk

Non-tailored intervention - Standard of practice

Clinical Study ID

NCT05824273
Pro2022-0860
7R01CA263662-02
  • Ages 50-80
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

LungTalk and leveraging Facebook-targeted Advertisement (FBTA) addresses the call to develop and test multi-level, cancer communication interventions using innovative methods and designs. The study's long term goal is to increase lung cancer screening uptake among appropriate, high-risk individuals nationwide.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • ≥20-pack-year smoking history;

  • Individuals who currently smoke or quit smoking within the past 15 years

Exclusion

Exclusion Criteria:

  • Previously undergone LDCT for early detection of lung cancer, have a lung nodule ornodules that are currently being followed

  • Has ever been diagnosed with lung cancer

  • Individuals with impaired decision-making (because our primary outcome isdecision-making, we will not include individuals with impaired decision-making)

Study Design

Total Participants: 512
Treatment Group(s): 2
Primary Treatment: LungTalk
Phase:
Study Start date:
August 02, 2023
Estimated Completion Date:
July 30, 2024

Connect with a study center

  • Hackensack Meridian Health - Center for Discovery and Innovation

    Nutley, New Jersey 07110
    United States

    Site Not Available

  • Hackensack Meridian Health - Center for Discovery and Innovation

    Nutley 5102076, New Jersey 5101760 07110
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.